Phase II, Single-arm Study of Vismodegib in Advanced Gastric Adenocarcinoma Patients With SMO Overexpression
Status: Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 18 Sep 2019
Price : $35 *
At a glance
- Drugs Vismodegib (Primary)
- Indications Adenocarcinoma; Gastric cancer
- Focus Therapeutic Use
- 17 May 2019 Planned End Date changed from 31 Dec 2018 to 30 Sep 2020.
- 17 May 2019 Planned primary completion date changed from 1 Nov 2018 to 31 Dec 2019.
- 17 May 2019 Status changed from recruiting to active, no longer recruiting.